HealthEquity (NASDAQ:HQY) Issues FY 2025 Earnings Guidance

HealthEquity (NASDAQ:HQY) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 2.790-2.960 for the period, compared to the consensus EPS estimate of 2.830. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion.

HealthEquity Price Performance

Shares of NASDAQ HQY opened at $79.85 on Friday. HealthEquity has a twelve month low of $48.86 and a twelve month high of $84.49. The company has a current ratio of 4.76, a quick ratio of 4.76 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $6.85 billion, a price-to-earnings ratio of 124.77, a price-to-earnings-growth ratio of 1.30 and a beta of 0.53. The business has a 50 day simple moving average of $80.84 and a 200-day simple moving average of $74.05.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Tuesday, March 19th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.08. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. The business had revenue of $262.39 million during the quarter, compared to the consensus estimate of $258.56 million. As a group, equities research analysts expect that HealthEquity will post 2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HQY. KeyCorp upped their price objective on HealthEquity from $85.00 to $95.00 and gave the stock an overweight rating in a research note on Friday, March 22nd. JPMorgan Chase & Co. upped their price objective on HealthEquity from $86.00 to $108.00 and gave the stock an overweight rating in a research note on Tuesday, April 2nd. Barrington Research restated an outperform rating and set a $100.00 price objective on shares of HealthEquity in a research note on Friday, March 22nd. Barclays upped their price objective on HealthEquity from $84.00 to $104.00 and gave the stock an overweight rating in a research note on Friday, February 23rd. Finally, Bank of America upped their price objective on HealthEquity from $93.00 to $97.00 and gave the stock a buy rating in a research note on Wednesday, March 20th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $96.17.

Insiders Place Their Bets

In other news, EVP Delano Ladd sold 2,499 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $80.00, for a total value of $199,920.00. Following the completion of the sale, the executive vice president now owns 49,996 shares in the company, valued at $3,999,680. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Evelyn S. Dilsaver sold 32,500 shares of the company’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total value of $2,576,925.00. Following the completion of the sale, the director now owns 32,123 shares in the company, valued at $2,547,032.67. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Delano Ladd sold 2,499 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $80.00, for a total value of $199,920.00. Following the sale, the executive vice president now directly owns 49,996 shares of the company’s stock, valued at $3,999,680. The disclosure for this sale can be found here. In the last quarter, insiders sold 71,322 shares of company stock worth $5,682,895. 2.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On HealthEquity

Several hedge funds have recently modified their holdings of HQY. Castleview Partners LLC purchased a new stake in shares of HealthEquity during the second quarter valued at $39,000. Lazard Asset Management LLC raised its position in HealthEquity by 117.9% during the third quarter. Lazard Asset Management LLC now owns 549 shares of the company’s stock valued at $40,000 after buying an additional 297 shares during the period. Coppell Advisory Solutions LLC acquired a new position in HealthEquity during the second quarter valued at $48,000. Belpointe Asset Management LLC raised its position in HealthEquity by 229.0% during the first quarter. Belpointe Asset Management LLC now owns 1,066 shares of the company’s stock valued at $63,000 after buying an additional 742 shares during the period. Finally, Quarry LP acquired a new position in HealthEquity in the 2nd quarter worth about $74,000. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.